Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 3/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097420 | 0.95 | UBE2M (0.41) | CASRCCR5UBE2MDCUN1D1SPTLC2 | |
| SCHEMBL1097659 | 0.89 | UBE2M (0.38) | CCR5UBE2MDCUN1D1P2RY12 | |
| SCHEMBL1096487 | 0.89 | CASR (0.40) | CASRCCR5CYP2D6SMN1; SMN2 | |
| SCHEMBL1096075 | 0.88 | CASR (0.34) | CASRUBE2MDCUN1D1P2RY12SMN1; SMN2 | |
| SCHEMBL1096451 | 0.86 | CASR (0.36) | CASRCCR5SPTLC2CYP2D6CCNK | |
| SCHEMBL1095781 | 0.86 | CCR5 (0.39) | CASRCCR5CYP2D6 | |
| SCHEMBL4095981 | 0.85 | CCR5 (0.37) | CASRCCR5CYP2D6 | |
| SCHEMBL1096960 | 0.85 | CASR (0.41) | CASRCCR5CYP2D6 | |
| SCHEMBL1095286 | 0.83 | NPY2R (0.42) | SMN1; SMN2 | |
| SCHEMBL1096628 | 0.82 | CASR (0.39) | CASRCCR5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CASR 1/4885EPHX2 2521/4885CCR5 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.